Cytek Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Cytek Biosciences

10/08/2022 22:03

* Cytek Biosciences Inc  CTKB.OQ  reported quarterly
adjusted
earnings of 3 cents​​ per share for the quarter ended in June.
The mean expectation of four analysts for the quarter was
for earnings of 2 cents per share.
    * Revenue rose 32.1% to $40.16 million from a year ago;
analysts
expected $39.63 million. 
    * Cytek Biosciences Inc's reported EPS for the quarter was
breakeven results​.
    * The mean earnings estimate of analysts had risen by
about 66.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cytek Biosciences Inc shares had risen by 36.9% this
quarter and
lost 10.0% so far this year.
    * The company reported a quarterly loss of $702 thousand.
    * Wall Street's median 12-month price target for Cytek
Biosciences
Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      0.02           0.03           Beat
 Mar. 31 2022      0.00           0.01           Beat
 Dec. 31 2021      0.03           0.03           Met
 Sep. 30 2021      0.02           0.02           Met